The Canadian pharmaceutical landscape is changing at a rapid pace. This includes recent updates to PMPRB regulations, a new CADTH compliance process and emerging opportunities in rare diseases — all against the backdrop of a pandemic-shaken health system. Determine the immediate and future impact on your business through dialogue with government, regulatory, industry and patient group leaders. Take away an action plan to:
- Uncover emerging opportunities within Canada’s impending national strategy for high-cost drugs for rare diseases.
- Incorporate best practices and lessons learned during the COVID-19 pandemic.
- Overcome early stumbling blocks surrounding the updated PMPRB regulations.
Prepare your organization for opportunity and risk in the ‘new normal.’